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a  b  s  t  r  a  c  t
INTRODUCTION:  Pancreatic  metastases  are  uncommon  and  only  found  in  a minority  of patients  with
widespread  metastatic  disease  at autopsy.  The  most  common  primary  cancer  site resulting  in  pancreatic
metastases  is the  kidney,  followed  by colorectal  cancer,  melanoma,  breast  cancer,  lung  carcinoma  and
sarcoma.
PRESENTATION  OF  CASE:  Herein,  we  report  a 63-year-old  male  patient  who  presented  −3.5  years  after
radical  nephrectomy  performed  for  renal  cell  carcinoma  (RCC)-with  a well-deﬁned  lobular,  round  mass
at the  body  of  the  pancreas  demonstrated  by abdominal  Magnetic  Resonance  Imaging  (MRI).  The patient
underwent  distal  pancreatectomy  combined  with  splenectomy  and  cholecystectomy.  Histopathological
examination  revealed  clusters  of epithelial  clear  cells,  immunohistochemically  positive  for  RCC  marker,
and negative  for  CD10  and  CA19-9.  A  ﬁnal  diagnosis  of clear  RCC  metastasizing  to pancreas  was  obtained
in  view  of  the  past  history  of RCC,  microscopy  and the immunoproﬁle.  This  was  the  second metachronous
disease  recurrence  after  a previous  metastatic  involvement  of  the  liver,  developed  19  months  from  the
initial  diagnosis.  The  patient  has  remained  well  at a  6  month  follow  up  post-resection.
DISCUSSION:  Solitary  pancreatic  metastases  may  be  misdiagnosed  as  primary  pancreatic  cancer.  However,
imaging  including  computed  tomography  (CT)  and  MRI,  may  discriminate  between  them.  Surgical  pro-
cedures  could  differentiate  solitary  metastasis  from  neuroendocrine  neoplasms.  The  optimal  resection
strategy  involves  adequate  resection  margins  and  maximal  tissue  preservation  of the pancreas.
CONCLUSION:  Recently,  an  increasing  number  of surgical  resections  have  been  performed  in  selected
patients  with  limited  metastatic  disease  to the  pancreas.  In  addition,  a rigid  follow-up  scheme,  including
endoscopic  ultrasound  (EUS)  and  CT is  essential  give  patients  a chance  for  a prolonged  life.
 Publi
he CC© 2016  The  Author(s).
access  article  under  t
. Introduction
Renal cell carcinoma (RCC) accounts for approximately 2% of all
dult malignancies and represents the third most common tumor of
enitourinary tract affecting 115,200 new cases and 49,000 deaths
n Europe [1]. RCC behavior is variable; up to 20% of cases may
ave periods of slow tumor growth or stability lasting many years.
n the meantime, 20%–30% of patients are diagnosed with metas-
ases at presentation, and the 5-year survival rate is less than 10%
nce metastases spread. Nevertheless pancreas is an unusual local-
zation of metastatic disease, the kidney being the most common
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primary cancer site resulting in an isolated pancreatic metastasis
which can occur a long time period after nephrectomy [2]. Patients
are usually asymptomatic or can present with weight loss, jaundice,
abdominal pain, or pancreatitis related to pancreatic duct obstruc-
tion [3].
Only few cases with pancreatico-duodenal metastasis were
described in the literature in which upper gastrointestinal bleeding
was the ﬁrst manifestation of malignant recurrence [4]. The long
disease free interval, from the time of nephrectomy to the diag-
nosis of metastasis, indicates a biological pattern of slow growth,
favouring local surgical resection. Therefore a long follow up is
indicated in patients with RCC [5]. At present, data are lacking on
the treatment of solitary pancreatic metastases of RCC with novel
targeted agents [6]; nevertheless, it may be reasonable to reserve
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. A and B: T2 weighted with Fat saturation image (Fig. 1A) and T1 weighted
(Fig. 1B) in axial plane at the same level of pancreas body. The lesion is depicted as a
high signal intensity and low to intermediate respectively, nodule. Part of the lesion
is  protruding out of the pancreatic body frontal contour.CASE  REPORT
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his medical approach for patients with distant lesions outside the
ancreas.
. Methods
This work has been reported in line with the CARE Guidelines [7].
. Case presentation
A 63-year-old male underwent a right sided radical nephrec-
omy for a RCC measuring 8 × 7 × 4 cm diagnosed in May  2012.
he tumor, with a Fuhrman nuclear grade of II, was conﬁned
o the kidney. No vascular or lymph node involvement was
evealed. The stage of the disease at the initial diagnosis was  II.
9 months later, the patient relapsed with a lesion measuring
.5 × 2.5 × 1.3 cm in the posterior surface of the liver. On the basis
f these ﬁndings, a partial hepatectomy with resection of segment
III of the liver was performed and no subsequent pharmaco-
ogical intervention was provided. In October 2015, the patient
as admitted with right upper quadrant pain and jaundice. There
as no history of a change in bowel habit, GI bleeding, pan-
reatitis, liver or gallbladder disease; nevertheless, recent weight
oss of about 2 kg as well as colic abdominal pain that resolved
pontaneously 2 months earlier, were reported. Physical exam-
nation revealed normal bowel sounds, deep jaundice and mild
enderness in the epigastrium and right upper quadrant, without
vidence of peripheral lymphadenopathy, palpable mass or hep-
tosplenomegaly.
Magnetic Reverse Cholangiopancreatography (MRCP) revealed
allbladder stones and further assessment with an abdominal
RI  demonstrated the presence of a well-deﬁned lobular, round
ass at the body of the pancreas measuring 1,4 × 1,3 × 1,5 cm
Fig. 1). There was no evidence of upstream pancreatic duct dila-
ion or signs of lymphatic inﬁltration. EUS conﬁrmed the above
ata and a double EUS-guided ﬁne needle aspiration (EUS-FNA)
as performed with a 22G biopsy needle. Subsequent cytologic
xamination of the specimen revealed a neoplastic population
onsisting of small and medium-sized malignant cells with scant
ytoplasm and various-sized hyperchromatic nuclei (Fig. 2). The
erformed immunohistochemical analysis of tumor cells was
ositive for RCC marker and negative for CD10 and CA19-9
Fig. 3).
Taking into consideration the patient’s medical history, this
ccupying lesion in the body of the pancreas was  suggestive
f metastasis from RCC. The patient underwent distal pancrea-
ectomy combined with splenectomy and cholecystectomy. Due
o the preceding surgical operation, adjuvant administration of
yrosine kinase inhibitors (TKIs) was not indicated. Therefore,
he management of the patient was restricted to life-long mon-
toring and no signs of disease progression were detected in
is recent clinical and radiological assessment six months post-
esection.
. Discussion
Pancreatic metastases are rare and account for only 2–5% of
etected lesions in this organ. RCC metastasizes to the pancreas
ith a slightly more common incidence compared to other tumors
nd this spread could occur as late as 10–32 years. Preoperative
iagnosis of pancreatic metastasis is a matter of challenge. An
ccurate histologic diagnosis of RCC spreading secondarily to the
ancreas is paramount in proper management, especially in the
bsence of a clinically relevant history. The clinical characteristics
f these metastatic lesions include abdominal pain, gastrointestinal
leeding, anemia and jaundice, though the majority of patients are
Fig. 2. Clear cell renal carcinoma composed of nests of cells with clear cytoplasm
(×100).
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Fornelli, M. Burzi, E. Vezzelli, E. Jovine, Analysis of prognostic factors inig. 3. CD10 positive membrane immunostaining in clear cell renal carcinoma
×40).
symptomatic and occasionally found in follow-up. They present
ith an indolent behavior and have better prognosis than pancre-
tic adenocarcinoma. Prognostic factors correlated with impaired
urvival among these patients are the presence of symptoms and
ccurrence of metastases in a time period less than 2 years [8].
arious tumor factors, including large diameter and high stage
roup as well as nuclear grade have been determined as impor-
ant risk factors for tumor recurrence. Patients with tumors greater
han 5 cm in greatest diameter had a greater frequency of tumor
ecurrence than those with tumors smaller than 5 cm in a study
P = 0.01) [9].
Metastases from RCC share morphological and imaging fea-
ures with endocrine pancreatic neoplasms and the differential
iagnosis between hypervascular metastases and nonfunctioning
euroendocrine tumors may  be problematic [10]. The CT scan char-
cteristics of the pancreatic metastases generally resembled those
f primary RCC, with well-deﬁned margins and greater enhance-
ent than a normal pancreas with a central area of low attenuation.
eripherally enhanced tumors are more likely to be metastatic
han primary pancreatic cancers, which tend to be non- or poorly-
nhanced masses [10]. On MRI  (with contrast), smaller lesions show
omogeneous enhancement whereas rim enhancement is noted
n larger lesions. The emergence of EUS – if feasible – has been
he diagnostic modality of choice for detecting even small lesions.
 fundamental principle for the indication of an EUS-FNA biopsy
s the determination of whether the information obtained has the
otential to affect patient management. An EUS-guided FNA biopsy
s examined in patients with a solid pancreatic mass suspected to
e a malignant tumor. FNA cytology though often non-speciﬁc for
CC metastases, might be performed preoperatively. However, for
esectable tumors, preoperative diagnosis would not alter the treat-
ent, and surgery without previously performed FNA biopsy is
easonable. Diagnostic approach to pancreatic cysts include EUS
maging; nevertheless, there are reports concerning a dissemi-
ation risk from EUS-FNA. The enhanced diagnostic capability of
US-FNA must be balanced against the risk of tumor seeding.
maller-gauge needles have similar cytology yields as large-gauge
eedles and additional advantage of greater ﬂexibility for difﬁcult
pproachable areas, such as the uncinate process [11]. In cases in
hich the initial EUS-FNA is negative for malignancy, if suspicion
emains high, surgical exploration or repeat EUS-FNA is advised.
ifferential diagnosis should be made especially from neuroen-
ocrine tumors of the pancreas [10].
The introduction of targeted agents (tyrosine kinase and Mam-
alian target of rapamycin inhibitors) has dramatically changedPEN  ACCESS
rgery Case Reports 27 (2016) 198–201
the therapeutic landscape of patients with metastatic RCC, improv-
ing their outcome [12]. However, surgical resection of pancreatic
metastases seems to play a crucial role in the management of
these patients paving the way for a possible cure. At that regard,
it is important to accurately diagnose pancreatic involvement by
metastatic RCC on histology, especially given that RCC metasta-
sis may  manifest more than a decade after its initial presentation
and diagnosis. Pancreatic metastases of RCC represent a relatively
indolent tumor phenotype, which further supports the strategy of
typical operation. Nevertheless, operations such as partial, distal
and total pancreatectomy are indicated in terms of tumor traits
and patients’ status. The selection of patients undergoing surgery
should be rational, taking into account life expectancy, comorbidity,
metastatic extent and tumor biology for the beneﬁt to be optimal.
In the largest series of cases with surgical resection of pancreatic
metastases from RCC, Schwarz et al. reported 3-, 5-, and 10-year
overall survival (OS) of 72, 63, and 32% respectively, highlighting
the long-term beneﬁcial impact of surgery in these patients [13].
The role of adjuvant and neoadjuvant targeted therapies remains
under investigation.
5. Conclusion
More clinical research is needed to elucidate the impact of both
surgery and targeted therapeutic interventions in the management
of patients with pancreatic metastases from RCC. Their behavior is
indolent, with long-term survival. Close and long-term follow-up
is important for designing optimal treatment, and these patients
should be evaluated with a multidisciplinary approach. A high
index of suspicion is required for patients with a history of RCC
and they should be provided lifelong multidisciplinary follow-up
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